# Management strategies for burning mouth syndrome: a comprehensive review

**Authors:** Federica Canfora, Noemi Coppola, Elena Calabria, Niccolò Giuseppe Armogida, Michele Davide Mignogna, Gianrico Spagnuolo, Daniela Adamo

PMC · DOI: 10.22514/jofph.2026.001 · 2026-01-12

## TL;DR

This paper reviews various treatment strategies for Burning Mouth Syndrome, including medications, therapies, and lifestyle changes to improve patient outcomes.

## Contribution

The paper provides a comprehensive overview of evolving management strategies for BMS, emphasizing functional recovery and multidisciplinary approaches.

## Key findings

- Pharmacological treatments like clonazepam and antidepressants show promise in managing BMS.
- Non-pharmacological interventions such as CBT and TMS can complement drug therapies.
- Lifestyle modifications and digital health resources are essential for holistic BMS management.

## Abstract

Burning Mouth Syndrome (BMS) is a complex chronic neuropathic orofacial pain 
disorder characterized by a persistent burning or dysesthetic sensation in the 
oral cavity without an identifiable organic cause. The management of BMS has 
evolved beyond symptom relief to focus on achieving full functional recovery 
(FFR), which encompasses restoring patients to their usual activities without 
restrictions, addressing both physical and psychological dimensions. Key 
pharmacological treatments such as clonazepam and capsaicin are explored in 
detail, alongside the potential of newer agents like various classes of 
antidepressants (including tricyclic antidepressants, selective serotonin 
reuptake inhibitors, and serotonin and noradrenaline reuptake inhibitors, 
vortioxetine) and antiepileptics showing promise in addressing the multifactorial 
nature of BMS. Non-pharmacological interventions, such as cognitive-behavioral 
therapy (CBT), low-level laser therapy (LLLT), and transcranial magnetic 
stimulation (TMS), are highlighted for their potential to complement 
pharmacological treatments. These interventions aim to modify pain perception, 
reduce psychological burdens, and enhance overall quality of life. Lifestyle 
modifications, including dietary changes, stress management techniques, improved 
sleep hygiene, and regular physical activity, are essential components of a 
holistic treatment plan that addresses modifiable risk factors affecting brain 
health. The integration of telemedicine and digital health resources is proposed 
to enhance patient management and accessibility to multidisciplinary 
care. This review provides a comprehensive update on all available 
therapeutic approaches for BMS, encompassing pharmacological treatments, 
non-pharmacotherapeutic interventions, and lifestyle optimization strategies, 
offering a holistic perspective on managing this condition.

## Linked entities

- **Chemicals:** clonazepam (PubChem CID 2802), capsaicin (PubChem CID 1548943)
- **Diseases:** Burning Mouth Syndrome (MONDO:0006687)

## Full-text entities

- **Genes:** Slc6a4 (solute carrier family 6 member 4) [NCBI Gene 25553] {aka SERT}, HTR7 (5-hydroxytryptamine receptor 7) [NCBI Gene 3363] {aka 5-HT7}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}, MT1IP (metallothionein 1I, pseudogene) [NCBI Gene 644314] {aka MT1, MT1I, MTE}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, LPO (lactoperoxidase) [NCBI Gene 4025] {aka SPO}, MT2A (metallothionein 2A) [NCBI Gene 4502] {aka MT-2, MT-II, MT2}, HTR1D (5-hydroxytryptamine receptor 1D) [NCBI Gene 3352] {aka 5-HT1D, HT1DA, HTR1DA, HTRL, RDC4}, GAD1 (glutamate decarboxylase 1) [NCBI Gene 2571] {aka CPSQ1, DEE89, GAD, GAD-67, SCP}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, HTR1B (5-hydroxytryptamine receptor 1B) [NCBI Gene 3351] {aka 5-HT-1B, 5-HT-1D-beta, 5-HT1B, 5-HT1DB, HTR1D2, HTR1DB}, SLC6A4 (solute carrier family 6 member 4) [NCBI Gene 6532] {aka 5-HTT, 5-HTTLPR, 5HTT, HTT, OCD1, SERT}, HTR1A (5-hydroxytryptamine receptor 1A) [NCBI Gene 3350] {aka 5-HT-1A, 5-HT1A, 5HT1a, ADRB2RL1, ADRBRL1, G-21}, HTR2A (5-hydroxytryptamine receptor 2A) [NCBI Gene 3356] {aka 5-HT2A, HTR2}, TAC1 (tachykinin precursor 1) [NCBI Gene 6863] {aka Hs.2563, NK2, NKNA, NPK, TAC2}, GPHA2 (glycoprotein hormone subunit alpha 2) [NCBI Gene 170589] {aka A2, GPA2, ZSIG51}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, KAR [NCBI Gene 8083], HTR3A (5-hydroxytryptamine receptor 3A) [NCBI Gene 3359] {aka 5-HT-3, 5-HT3A, 5-HT3R, 5HT3R, HTR3}, PRL (prolactin) [NCBI Gene 5617] {aka GHA1, pPRL}, CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}, FAAH (fatty acid amide hydrolase) [NCBI Gene 2166] {aka FAAH-1, FAAH1, PSAB}
- **Diseases:** obesity (MESH:D009765), QT interval (OMIM:610141), blurred vision (MESH:D014786), confusion (MESH:D003221), withdrawal (MESH:D013375), lethargic depression (MESH:D004674), schizophrenia (MESH:D012559), brain frailty (MESH:D000073496), osteoarthritis (MESH:D010003), nociceptive (MESH:D059226), stroke (MESH:D020521), musculoskeletal disorders (MESH:D009140), mucosal damage (MESH:D052016), bulimia (MESH:D002032), hypertension (MESH:D006973), neuropsychiatric conditions (MESH:D001523), neurodegenerative diseases (MESH:D019636), PTSD (MESH:D013313), chronic pain (MESH:D059350), seizures (MESH:D012640), fatigue (MESH:D005221), extrapyramidal symptoms (MESH:D001480), urinary retention (MESH:D016055), diabetic neuropathy (MESH:D003929), drug dependency (MESH:D019966), ulceration (MESH:D014456), trigeminal neuralgia (MESH:D014277), sexual dysfunction (MESH:D012735), MDD (MESH:D003865), muscle tension (MESH:D018781), neuropathic orofacial pain  disorder (MESH:D009437), chronic low back pain (MESH:D017116), cytotoxicity (MESH:D064420), fibromyalgia (MESH:D005356), acute and chronic pain (MESH:D059787), dry mouth (MESH:D014987), Diabetic peripheral neuropathy (MESH:D010523), analgesia (MESH:D000699), nausea (MESH:D009325), metabolic syndrome (MESH:D024821), premature ejaculation (MESH:D061686), OCD (MESH:D009771), Depression (MESH:D003866), dizziness (MESH:D004244), AD (MESH:D000544), headache (MESH:D006261), hyperalgesia (MESH:D006930), cognitive decline (MESH:D003072), dysgeusia (MESH:D004408), constipation (MESH:D003248), anxiety  disorders (MESH:D001008), vitamin  deficiencies (MESH:D014802), sleep  disorders (MESH:D012893), Orofacial Pain (MESH:D005157), sialorrhea (MESH:D012798), nociplastic pain condition (MESH:D013001), BMS (MESH:D002054), QT prolongation (MESH:D008133), pain (MESH:D010146), somnolence (MESH:D006970)
- **Chemicals:** N (MESH:D009584), glutamate (MESH:D018698), lidocaine (MESH:D008012), calcium (MESH:D002118), histamine (MESH:D006632), lipid (MESH:D008055), Clonazepam (MESH:D002998), milnacipran (MESH:D000078764), aripiprazole (MESH:D000068180), escitalopram (MESH:D000089983), sugar (MESH:D000073893), acetylcholine (MESH:D000109), PGB (MESH:D000069583), dopamine (MESH:D004298), duloxetine (MESH:D000068736), cannabinoid (MESH:D002186), anandamide (MESH:C078814), paroxetine (MESH:D017374), sodium (MESH:D012964), Cl- (MESH:D002713), Melatonin (MESH:D008550), venlafaxine (MESH:D000069470), Ads (-), catecholamine (MESH:D002395), nortriptyline (MESH:D009661), sucralfate (MESH:D013392), endocannabinoids (MESH:D063388), Sertraline (MESH:D020280), ALA (MESH:D008063), amisulpride (MESH:D000077582), levosulpiride (MESH:C078143), Capsaicin (MESH:D002211), amine (MESH:D000588), citalopram (MESH:D015283), B12 (MESH:C034730), benzydamine hydrochloride (MESH:D001591), GB (MESH:D000077206), GABA (MESH:D005680), olanzapine (MESH:D000077152), urea (MESH:D014508), chloride (MESH:D002712), Trazodone (MESH:D014196), benzodiazepine (MESH:D001569), cholesterol (MESH:D002784), 5HT (MESH:D012701), quetiapine (MESH:D000069348), Fluoxetine (MESH:D005473), PEA (MESH:C005958), water (MESH:D014867), amitriptyline (MESH:D000639), Noradrenaline (MESH:D009638), VO (MESH:D000078784), folate (MESH:D005492), alcohol (MESH:D000438)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Rodentia (rodent, order) [taxon 9989]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12853153/full.md

---
Source: https://tomesphere.com/paper/PMC12853153